Etelcalcetide in Patients on Hemodialysis with Severe Secondary Hyperparathyroidism. Multicenter Study in “Real Life”

Etelcalcetide in Patients on Hemodialysis with Severe Secondary Hyperparathyroidism. Multicenter Study in “Real Life”

Etelcalcetide is a new calcimimetic indicated for the treatment of secondary hyperparathyroidism (SHPT) in dialysis patients. Etelcalcetide efficacy in SHPT has been ascertained only in randomized controlled trials. This multicenter study was carried out in “real world” setting t...

Full description

Bibliographic Details
Main Authors: Domenico Russo, Rocco Tripepi, Fabio Malberti, Biagio Di Iorio, Bernadette Scognamiglio, Luca Di Lullo, Immacolata Gaia Paduano, Giovanni Luigi Tripepi, Vincenzo Antonio Panuccio
Format: Article
Language:English
Published: MDPI AG 2019-07-01
Series:Journal of Clinical Medicine
Subjects:
secondary hyperparathyroidism
cinacalcet
etelcalcetide
hypocalcemia
gastrointestinal side effects
Online Access:https://www.mdpi.com/2077-0383/8/7/1066

Internet

https://www.mdpi.com/2077-0383/8/7/1066

Similar Items